Stammzellen - iPS-Zellen - Genomeditierung. Stem Cells - iPS Cells - Genome Editing

The use of stem cells, iPS cells and genetic engineering methods such as genome editing are tools for the development of new therapies in regenerative medicine. The implementation of such therapies does not only raise scientific, -technological and medical issues, but also those of an ethical, legal, social and economic nature. Therefore, the successful implementation of regenerative medicine therapies relies on a cross-disciplinary approach. Aspects of the use of stem cells, iPS cells and genome editing in research and therapy were discussed at both an interdisciplinary and international symposium and a conference funded by the BMBF (the Federal Ministry of Education and Research in Germany). They both focused on the regulatory handling of such therapies and constitutional questions regarding the commercialisation of human cells and patent issues. With contributions by Insa S. Schröder; Susanne Müller and Timo Faltus; Inesa Chmurec; Tereza Hendl; Calvin Wai Loon Ho; Kalina Kamenova; Delphine Pichereau and Emmanuelle Rial-Sebbag; Hannah Schickl; Elena Buglo and Stephan Zuchner; Jochen Taupitz and Juliane Boscheinen; Winfried Kluth; Susanne Beck and Frederike Seitz; Timo Faltus; Rosario Isasi; Katrin Vohland, Julia Diekämper, Alexandra Moormann, Tobias Nettke and Wiebke Rössig; Hans Zillmann and Matthias Kaufmann; Ulrich Storz; Timo Faltus.